Vincerx Pharma, Inc.

OTCPK:VINC Stock Report

Market Cap: US$266.4k

Vincerx Pharma Management

Management criteria checks 2/4

Vincerx Pharma's CEO is Raquel Izumi, appointed in Dec 2024, has a tenure of less than a year. total yearly compensation is $1.78M, comprised of 25.4% salary and 74.6% bonuses, including company stock and options. directly owns 1.63% of the company’s shares, worth $4.34K. The average tenure of the management team and the board of directors is 2.8 years and 3.1 years respectively.

Key information

Raquel Izumi

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage25.40%
CEO tenureless than a year
CEO ownership1.6%
Management average tenure2.8yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely

Aug 21
Here's Why Vincerx Pharma (NASDAQ:VINC) Must Use Its Cash Wisely

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Jul 18
Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Mar 30
Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Sep 22
Can Vincerx Pharma (NASDAQ:VINC) Afford To Invest In Growth?

Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?

Jun 24
Is Vincerx Pharma (NASDAQ:VINC) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Raquel Izumi's remuneration changed compared to Vincerx Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$23m

Dec 31 2024US$2mUS$452k

-US$30m

Sep 30 2024n/an/a

-US$27m

Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$38m

Dec 31 2023US$538kUS$448k

-US$40m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$54m

Mar 31 2023n/an/a

-US$61m

Dec 31 2022US$997kUS$430k

-US$63m

Sep 30 2022n/an/a

-US$58m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$49m

Dec 31 2021US$2mUS$325k

-US$39m

Sep 30 2021n/an/a

-US$49m

Jun 30 2021n/an/a

-US$25m

Mar 31 2021n/an/a

-US$23m

Dec 31 2020US$653kUS$16k

-US$17m

Compensation vs Market: Raquel's total compensation ($USD1.78M) is above average for companies of similar size in the US market ($USD611.00K).

Compensation vs Earnings: Raquel's compensation has increased whilst the company is unprofitable.

CEO

Raquel Izumi (55 yo)

less than a year
Tenure
US$1,777,285
Compensation

Dr. Raquel E. Izumi, Ph D., is serving as Advisor at Pragma Biosciences, Inc. from February 2025. She is Co-Founder of Vincerx Pharma, Inc. (formerly known as Vincera Pharma, Inc.) and served as its Chief...

Leadership Team

NamePositionTenureCompensationOwnership
Raquel Izumi
Co-Founderless than a yearUS$1.78m1.63%
$ 4.3k
Tom Thomas
Consultantless than a yearUS$1.47mno data
Alexander Seelenberger
Consultantless than a yearUS$1.47m0.036%
$ 97.1
John Byrd
Founder & Chairman of Scientific Advisory Boardno datano data1.55%
$ 4.1k
Kevin Haas
Acting CFO2.8yrsno data0.041%
$ 108.9
Hans-Georg Lerchen
Chief Scientific Officer4.6yrsno datano data
Gabriela Jairala
VP of Investor Relations & Corporate Communications and Chief of Staff2.3yrsno datano data
Karen Quarford
Vice President of Quality Operations & Compliance2.8yrsno datano data
Melissa Merrick
Senior Director of People & Culture and Head of Human Resource4.2yrsno datano data
Beatrix Stelte-Ludwig
Executive Chief Development Officer4.4yrsno datano data
2.8yrs
Average Tenure
57.5yo
Average Age

Experienced Management: VINC's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Raquel Izumi
Co-Founder5.8yrsUS$1.78m1.63%
$ 4.3k
John Byrd
Founder & Chairman of Scientific Advisory Board4.5yrsno data1.55%
$ 4.1k
Anthony Tolcher
Member of Scientific Advisory Board4.5yrsno datano data
Howard Burris
Member of Scientific Advisory Board4.5yrsno datano data
Ian Flinn
Member of Scientific Advisory Board4.5yrsno datano data
Andre Goy
Member of Scientific Advisory Board4.5yrsno datano data
Amer Zeidan
Member of Scientific Advisory Board1.8yrsno datano data
Naval Daver
Member of Scientific Advisory Board1.8yrsno datano data
Marina Konopleva
Member of Scientific Advisory Board1.8yrsno datano data
Uma Borate
Member of Scientific Advisory Board1.8yrsno datano data
Apostolia Tsimberidou
Member of Scientific Advisory Board1.8yrsno datano data
Alice Mims
Member of Scientific Advisory Board1.8yrsno datano data
3.1yrs
Average Tenure

Experienced Board: VINC's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/05 00:58
End of Day Share Price 2025/10/03 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vincerx Pharma, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kalpit PatelB. Riley Securities, Inc.
I-Eh JenLaidlaw & Company (UK) Ltd